seed
Stage
1
Investors
About
STRM.BIO develops non-viral, megakaryocyte-derived extracellular vesicle platforms for in vivo gene therapy delivery, focusing on hematological diseases and CAR-T therapies.
Explore STRM.BIO's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.